Crescenzo D'alterio
Naples, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).
Journal: Cancer immunology, immunotherapy : CII
Published: January 16, 2025
Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modification.
Journal: European journal of medicinal chemistry
Published: July 21, 2024
Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites.
Journal: European journal of medicinal chemistry
Published: May 20, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 08, 2024
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
Journal: British journal of cancer
Published: September 20, 2023
Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment.
Journal: Hepatology international
Published: December 27, 2022
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.
Journal: Journal for immunotherapy of cancer
Published: January 18, 2022
Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection.
Journal: Therapeutic advances in medical oncology
Published: March 05, 2021
Last Updated: 09/26/2026